ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2008

Aug 22, 2008

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2008-08-21

Reporting Person: Clendeninn Neil James (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2008-08-21	Stock Option (right to buy)	$3.8915	A	2393	Acquired	2011-09-16	Common Stock (2393)	Direct
2008-08-21	Stock Option (right to buy)	$3.8915	A	952	Acquired	2011-12-20	Common Stock (952)	Direct
2008-08-21	Stock Option (right to buy)	$4.1077	A	3699	Acquired	2012-08-08	Common Stock (3699)	Direct
2008-08-21	Stock Option (right to buy)	$4.1077	A	513	Acquired	2013-03-23	Common Stock (513)	Direct
2008-08-21	Stock Option (right to buy)	$18.9384	A	3046	Acquired	2014-06-28	Common Stock (3046)	Direct

Footnotes

F1: Received in exchange for a stock option to acquire 11,000 shares of OncoGenex Technologies Inc. ("OncoGenex Technologies")
common stock for CAD$0.90 per share in connection with an arrangement between OncoGenex Technologies and OncoGenex
Pharmaceuticals, Inc. (the "Arrangement").

F2: Received in the Arrangement in exchange for a stock option to acquire 4,375 shares of OncoGenex Technologies common stock for
CAD$0.90 per share.

F3: Received in the Arrangement in exchange for a stock option to acquire 17,000 shares of OncoGenex Technologies common stock
for CAD$0.95 per share.

F4: Received in the Arrangement in exchange for a stock option to acquire 2,359 shares of OncoGenex Technologies common stock for
CAD$0.95 per share.

F5: Received in the Arrangement in exchange for a stock option to acquire 14,000 shares of OncoGenex Technologies common stock
for CAD$4.38 per share.